VTAK - catheterprecision.com Income before deduction of interest, taxes and amortization

Current EBITDA figures demonstrate the resilience of VIVO's IT algorithms for 3D visualization of arrhythmia foci, with the value stabilizing at 0.00. The business relies on non-invasive cardiac mapping that minimizes operational risks. High surgeon confidence confirms the status of Catheter Precision (VTAK) as an authoritative developer of precision pathology localization systems in electrophysiology.

Catheter Precision Inc (VTAK) Operating profit before deduction of amortization: for the period 11/23/2025 - 10/05/2026

Summary analytical data breakdowns for Catheter Precision, Inc. (VTAK)

- current price and projected stock value:

Price Catheter Precision Corporation|VTAK - Analyst Consensus Forecast

- market capitalization statistics:

Market Value Catheter Precision|VTAK - Enterprise Value

- book capitalization information:

Net Asset Value per Share Catheter Precision|VTAK - Company Net Assets|Market Cap to Book Value Multiple catheterprecision.com|VTAK - Company Total Assets

- business debt structure and liquidity details:

- earnings and market multiples details:

VTAK - Net Profit|Expected Net Profit Catheter Precision|VTAK - P/E Multiple|Projected Price to Earnings catheterprecision.com|VTAK - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Catheter Precision|VTAK - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Catheter Precision|VTAK - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months catheterprecision.com|VTAK - Earnings per share growth in current year|Expected net earnings per share growth next year Catheter Precision

Fundamental company valuation:Catheter Precision Corporation

Manufactured product of Catheter Precision Inc

This indicator serves as a key filter during asset stress testing, allowing investors to separate paper profits from actual cash flow. By analyzing absolute EBITDA dynamics, an investor assesses the operational efficiency of Catheter Precision (VTAK), where steady growth of this metric confirms the commercial success of implementing navigation systems in electrophysiology labs and the precision of executing catheter technologies in the treatment of arrhythmias.

Competitors of Catheter Precision (VTAK)